Antisense Therapeutics Ltd banner

Antisense Therapeutics Ltd
ASX:ANP

Watchlist Manager
Antisense Therapeutics Ltd Logo
Antisense Therapeutics Ltd
ASX:ANP
Watchlist
Price: 0.084 AUD 1.2% Market Closed
Market Cap: AU$75.7m

Multiples-Based Value

There is not enough data to reliably calculate the multiples-based value of ANP.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ANP Multiples-Based Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

ANP Competitors Multiples
Antisense Therapeutics Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Antisense Therapeutics Ltd
ASX:ANP
75.7m AUD 196.7 -6.7 -5.7 -5.7
US
Eli Lilly and Co
NYSE:LLY
875.9B USD 13.4 42.4 28.6 30.6
US
Johnson & Johnson
NYSE:JNJ
580.2B USD 6.2 21.6 15 18.5
UK
AstraZeneca PLC
LSE:AZN
237.5B GBP 5.2 30.1 16.6 23.5
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.7 11.6 13.1
US
Merck & Co Inc
NYSE:MRK
299.1B USD 4.6 16.4 10.2 12.4
CH
Novartis AG
SIX:NOVN
236.4B CHF 5.1 20.7 12.8 16.4
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6 386.8 970
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.2 7.5 8.8
US
Pfizer Inc
NYSE:PFE
158.2B USD 2.5 20.4 7.8 10.4
US
Bristol-Myers Squibb Co
NYSE:BMY
119.4B USD 2.5 16.9 7.1 8.8
P/E Multiple
Earnings Growth PEG
AU
Antisense Therapeutics Ltd
ASX:ANP
Average P/E: 22
Negative Multiple: -6.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.4
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.6
7%
3.1
UK
AstraZeneca PLC
LSE:AZN
30.1
26%
1.2
CH
Roche Holding AG
SIX:ROG
19.7
14%
1.4
US
Merck & Co Inc
NYSE:MRK
16.4
14%
1.2
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
1%
10.2
US
Pfizer Inc
NYSE:PFE
20.4
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.9
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Antisense Therapeutics Ltd
ASX:ANP
Average EV/EBITDA: 50.4
Negative Multiple: -5.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28.6
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15
2%
7.5
UK
AstraZeneca PLC
LSE:AZN
16.6
13%
1.3
CH
Roche Holding AG
SIX:ROG
11.6
6%
1.9
US
Merck & Co Inc
NYSE:MRK
10.2
3%
3.4
CH
Novartis AG
SIX:NOVN
12.8
5%
2.6
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.5
1%
7.5
US
Pfizer Inc
NYSE:PFE
7.8
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Antisense Therapeutics Ltd
ASX:ANP
Average EV/EBIT: 111.2
Negative Multiple: -5.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
30.6
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.5
6%
3.1
UK
AstraZeneca PLC
LSE:AZN
23.5
21%
1.1
CH
Roche Holding AG
SIX:ROG
13.1
6%
2.2
US
Merck & Co Inc
NYSE:MRK
12.4
6%
2.1
CH
Novartis AG
SIX:NOVN
16.4
9%
1.8
IE
E
Endo International PLC
LSE:0Y5F
970
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.8
2%
4.4
US
Pfizer Inc
NYSE:PFE
10.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett